Learn About DUROLANE Through a Peer-to-Peer Medical Education Event

Please provide your contact information, and we will reserve your spot in a peer-to-peer medical education event. Once spots have been filled, we will contact you with additional details on a time, date, and location.

Customer Service

T: 1-855-771-0606
E: canada.durolane@bioventusglobal.com

Bioventus Global

www.bioventusglobal.com

Disclaimer

Bioventus will never make your email address available to third parties, except to distribute requested materials. Any complaints or adverse reaction messages may be sent to complaints@bioventusglobal.com.

Summary of Indications: DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been licenced for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes. Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site.

Learn About DUROLANE Through a Peer-to-Peer Medical Education Event

Customer Service

Bioventus Global

Disclaimer

Attend a Peer-to-Peer Medical Education Event

Summary of Indications: DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been licenced for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes. Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling, or by clicking the Instructions for Use link located at the bottom of the page.